首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症液體活檢

市場調查報告書

商品編碼

1560795

全球乳癌液體活體組織切片市場 - 2024 - 2031

Global Breast Cancer Liquid Biopsy Market - 2024 - 2031

出版日期: 2024年09月23日 | 出版商:

DataM Intelligence | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

報告概述

全球乳癌液體切片市場在2023年達到16億美元，預計2031年將達到79.8億美元，2024-2031年預測期間複合年成長率為23.2%。

液體活體組織切片是對血液、尿液或其他體液樣本進行的實驗室測試，以尋找腫瘤中的癌細胞或腫瘤細胞釋放到人體體液中的小片段 DNA、RNA 或其他分子。液體活體組織切片可以隨著時間的推移採集多個樣本，這可能有助於醫生了解腫瘤中正在發生什麼樣的遺傳或分子變化。液體活體組織切片可用於幫助早期發現癌症。它也可用於幫助計劃治療或了解治療效果如何或癌症是否復發。

它由不同的生物基質組成，例如循環腫瘤細胞（CTC）、無細胞核酸、外泌體或腫瘤「教育血小板」。在許多情況下，微流體的使用極大地促進了最近的技術和分子進步，使得純化和分析液體活體組織切片成分的能力取得了巨大進步。

市場動態：

司機

乳癌盛行率增加

乳癌液體活體組織切片市場的需求是由多種因素驅動的。乳癌盛行率的上升推動了市場的成長。

此外，人們意識的提高和技術進步將推動對治療的需求。例如，根據 uicc.org 的數據，乳癌是全球女性中診斷最多的癌症，也是 157 個國家女性中診斷最多的癌症，佔癌症病例的四分之一。它是兩性中第二常見的癌症，也是女性癌症死亡的主要原因。預計到 2022 年將有 230 萬新發乳癌病例，全球診斷出的男女癌症中大約每 9 例就有 1 例是乳癌。 2022 年，估計有 669,418 人死於乳癌，其中大部分死亡發生在資源匱乏的地區。

此外，據breastcancer.org稱，大約66%的乳癌病例是在癌症擴散到乳房之外之前最容易治療的局部階段被診斷出來的。目前美國有超過四百萬女性有乳癌病史。

此外，根據世界衛生組織2023年2月發布的一篇文章，每年有超過230萬例乳癌病例，這使其成為成人中最常見的癌症。在 95% 的國家中，乳癌是女性癌症死亡的第一或第二大原因。然而，乳癌的存活率在國家之間和國家內部存在廣泛不平等，近 80% 的乳癌和子宮頸癌死亡發生在低收入和中等收入國家。

限制

液體活體組織切片相關的高成本、熟練專業人員的短缺以及批准新療法的嚴格監管要求等因素預計將阻礙市場。

細分市場分析

全球乳癌液體活體組織切片市場根據產品類型、循環生物標記、應用、最終用戶和地區進行細分。

循環腫瘤細胞（CTC）部分約佔全球乳癌液體切片市場佔有率的47.9%

預計循環腫瘤細胞細分市場將在預測期內佔據最大的市場佔有率。在這一領域，技術進步以及私人製造商用於研究工作的資金不斷增加將推動該市場的發展。

循環腫瘤細胞（CTC）作為液體活體組織切片在臨床應用和基礎癌症研究中具有巨大潛力。液體活體組織切片是一種微創技術，可以直接從體液中檢測癌症生物標記。在這些生物標記中，CTC、遊離 DNA (cfDNA) 和 RNA 提供了對腫瘤遺傳景觀的動態了解。這種革命性的方法為早期癌症檢測、監測疾病進展和客製化個人化治療策略提供了一個有前景的途徑。

CTC 現在被認為是轉移過程中的關鍵參與者。它們的檢測和分析為液體活體組織切片技術的發展鋪平了道路，為傳統組織活體組織切片提供了微創替代方案。這種創新方法徹底改變了我們對腫瘤動態的理解，實現即時監測並提供對腫瘤異質性、治療反應和疾病進展的見解。

市場地理分析

北美約佔全球乳癌液體切片市場佔有率的42.8%

預計北美地區將在預測期內佔據最大的市場佔有率。該地區乳癌發病率的上升以及人們意識的提高有助於推動市場發展。

例如，根據 Breastcancer.org 的數據，大約 13%（約八分之一）的美國女性在一生中會罹患侵襲性乳癌。近年來，發病率每年略有增加0.5%。乳癌仍然是美國女性癌症相關死亡的主要原因之一，僅次於肺癌。乳癌是美國女性中繼皮膚癌之後最常見的癌症。每年，大約 30% 的女性新診斷癌症是乳癌。目前美國有超過四百萬女性有乳癌病史。

此外，2023年6月，Labcorp推出液體切片檢查來檢測癌症相關生物標記。 Plasma Focus 液體切片檢查僅需標準抽血即可進行。它透過樣本尋找腫瘤細胞釋放到血液中的遊離 DNA (cfDNA) 片段，這可能有助於深入了解對特定患者最有效的癌症治療方法。

A liquid biopsy is a laboratory test done on a sample of blood, urine, or other body fluid to look for cancer cells from a tumor or small pieces of DNA, RNA, or other molecules released by tumor cells into a person's body fluids. Liquid biopsy allows multiple samples to be taken over time, which may help doctors understand what kind of genetic or molecular changes are taking place in a tumor. A liquid biopsy may be used to help find cancer at an early stage. It may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back.

It is composed of different biological matrices such as circulating tumor cells (CTCs), cell-free nucleic acids, exosomes or tumors "educated platelets." Recent technological and molecular advances, greatly facilitated by the use of microfluidics in many cases, have permitted large progress in both the ability to purify and analyze liquid biopsy components.

Market Dynamics: Drivers

Increasing prevalence of breast cancer

The demand for the breast cancer liquid biopsy market is driven by multiple factors. The rising prevalence of breast cancer propels the market growth.

Furthermore, the demand for treatment will be fueled by the increase in awareness among people and technological advancements. For instance, according to uicc.org, Breast cancer is the most diagnosed cancer among women worldwide and is the most diagnosed cancer in women in 157 countries, accounting for 1 in 4 cancer cases. It is the second most frequent cancer amongst both sexes and is the leading cause of death from cancer in women. With the estimated 2.3 million new cases of breast cancer in 2022, roughly one in every 9 cancers for both sexes diagnosed globally was breast cancer. In 2022, there were an estimated 669,418 deaths from breast cancer, with a disproportionate number of these deaths occurring in low-resource settings.

Moreover, according to breastcancer.org, About 66% of breast cancer cases are diagnosed at a localized stage before cancer has spread outside of the breast when it is easiest to treat. There are currently more than four million women with a history of breast cancer in the US.

Moreover, according to an article posted by WHO in February 2023, there are more than 2.3 million cases of breast cancer that occur each year, which makes it the most common cancer among adults. In 95% of countries, breast cancer is the first or second leading cause of female cancer deaths. Yet, survival from breast cancer is widely inequitable between and within countries nearly 80% of deaths from breast and cervical cancer occur in low- and middle-income countries.

Restraints

Factors such as high costs associated with liquid biopsy, the shortage of skilled professionals, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market.

Market Segment Analysis

The global breast cancer liquid biopsy market is segmented based on product type, circulating biomarkers, application, end-user, and region.

The segment circulating tumor cells (CTCs) accounted for approximately 47.9% of the global breast cancer liquid biopsy market share

The circulating tumor cells segment is expected to hold the largest market share over the forecast period. In this segment, the technological advancements, and rising funds for private manufacturers for research work would drive this market.

Circulating tumor cells (CTCs) as a liquid biopsy have great potential in clinical applications and basic cancer research. Liquid biopsy, a minimally invasive technique, allows for the detection of cancer biomarkers directly from bodily fluids. Among these biomarkers, CTCs, cell-free DNA (cfDNA), and RNA provide a dynamic glimpse into the tumor's genetic landscape. This revolutionary approach offers promising avenues for early cancer detection, monitoring disease progression, and tailoring personalized treatment strategies.

CTCs are now recognized as crucial players in the metastatic process. Their detection and analysis have paved the way for the development of liquid biopsy techniques, offering a minimally invasive alternative to traditional tissue biopsies. This innovative approach has revolutionized our understanding of tumor dynamics, enabling real-time monitoring and providing insights into tumor heterogeneity, treatment response, and disease progression.

Market Geographical Analysis

North America accounted for approximately 42.8% of the global breast cancer liquid biopsy market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of breast cancer, and growing awareness among people, in this region, help to propel the market.

For instance, according to breastcancer.org, approximately 13% (about one in eight) of U.S. women will develop invasive breast cancer in the course of their life. In recent years, incidence rates have increased slightly by 0.5% per year. Breast cancer is still one of the leading causes of cancer-related death in U.S. women, second only to lung cancer. Breast cancer is the most commonly diagnosed cancer among U.S. women after skin cancers. Each year, about 30% of all newly diagnosed cancers in women are breast cancer. There are currently more than four million women with a history of breast cancer in the US.

Moreover in June 2023, Labcorp launched liquid biopsy to detect cancer-related biomarkers. The Plasma Focus liquid biopsy requires only a standard blood draw to run. It looks through the sample for bits of cell-free DNA (cfDNA) that are released by tumor cells into the bloodstream and that may offer insights into the cancer treatments that'll work most effectively for a specific patient.

Market Segmentation

By Product Type

Reagents & Kits

Instruments

By Circulating Biomarkers

Circulating Tumor Cells (CTCs)

Circulating Cell-free DNA (cfDNA)

Extracellular Vesicles (EVs)

Others

By Application

Early Screening

Treatment Selection

By End-User

Hospitals

Diagnostic Centers

Research and Educational Institutions

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the global breast cancer liquid biopsy market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Agilent Technologies Inc., Merck KGaA, Cell Signaling Technology Inc., Medtronic, Bio-Rad Laboratories Inc., ExoDx, and Biocept Inc. among others.

Key Developments

On September 2023, nRichDX(R) launched its new RUO-labeled CTC enrichment kit that uniquely isolates Circulating Tumor Cells (CTCs) from up to 40mL of whole blood samples to help researchers advance liquid biopsy assay research and development.

Why Purchase the Report?

To visualize the global breast cancer liquid biopsy market segmentation based on product type, circulating biomarkers, application, end-user, and region, as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development

Excel data sheet with numerous data points of global breast cancer liquid biopsy market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global breast cancer liquid biopsy market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Circulating Biomarkers
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Prevalence of Breast Cancer
  - 4.1.1.2. Increasing Awareness Among People
  - 4.1.1.3. Technological Advancements
4.2. Restraints
- 4.2.1. High Costs Associated with Liquid Biopsy
- 4.2.2. Shortage of Skilled Professionals
- 4.2.3. Stringent Regulatory Requirements
4.3. Opportunity
4.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Reagents and Kits*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Instruments

7. By Circulating Biomarkers

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
- 7.1.2. Market Attractiveness Index, By Circulating Biomarkers
7.2. Circulating Tumor Cells (CTCs)*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Circulating Cell-free DNA (cfDNA)
7.4. Extracellular Vesicles
7.5. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Early Screening*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Treatment Selection

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Research and Educational Institutions
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. The U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. UK
  - 10.3.7.3. France
  - 10.3.7.4. Italy
  - 10.3.7.5. Spain
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulatory Biomarkers
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulatory Biomarkers
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. F. Hoffmann-La Roche Ltd. *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Thermo Fisher Scientific Inc.
12.3. Abbott
12.4. Agilent Technologies Inc.
12.5. Merck KGaA
12.6. Cell Signaling Technology Inc.
12.7. Medtronic
12.8. Bio-Rad Laboratories Inc.
12.9. ExoDx
12.10. Biocept Inc. (*LIST NOT EXHAUSTIVE)